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Introduction. Chronic rejection remains the leading cause of long-term morbidity and mortality after lung transplantation (NPT).
Appears during the ﬁrst 2 years after transplantation and manifests with progressive functional decline and hyperinﬂation
pulmonary obstructive pattern. The treatment is not well established, including high-dose corticosteroids, immunosuppressive
change, immunomodulatory drugs, and the overall nodal irradiation (INT) to interfere in the allogeneic response to the graft and
thus provide additional immunosuppression.
Clinical case. 57 year old woman diagnosed of pulmonary emphysema in May’10 Stage IV, refractory to medical treatment, so in
July’11 undergoing double lung transplant. A2 acute rejection that responded to steroids postoperatively and continued controls
respiratory function. In Dic’11 had a FEV1=2.79 l, which decreased, presenting in August’12 signiﬁcant functional impairment
(FEV1=1.9 l). Box is considered compatible with restrictive syndrome Graft and amending immunosuppression without getting
reverse the situation, so the box is diagnosed as chronic rejection of the NPT Assessment is decided on areas nodal radiotherapy
to stop the rejection. 8Gy have been administered to 0.8Gy per session (2 sessions per week) on chains lower cervical, supracla-
vicular, axillary, mediastinal, paraaortic, iliac and femoral, and thymic and splenic space. Have been identiﬁed risk organs (lungs
V5=0%, mean dose=150 cGy). The treatment was performed in an accelerator with multileaf ONCOR and energy of 6 and 15MV.
Tolerance to treatment was good, and without deterioration of respiratory function.
Conclusion. Although there is little literature, only small series, the INT in cases of chronic rejection post-NPT is an effective
treatment (reduced FEV1 decline) and well tolerated, it should be individualized for each case.
http://dx.doi.org/10.1016/j.rpor.2013.03.384
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Introduction. Advances in MRI/PET-CT planiﬁcation, intensity modulated radiation therapy (IMRT), fractionated stereotactic radi-
ation therapy (FSRT), stereotactic body radiation therapy (SBRT) and image guided radiotherapy (IGRT), are enhance strategies
for the treatment of pediatric tumors.
Objective. To describe how MRI, PET-CT, IGRT, IMRT, FSRT and SBRT have been incorporated to radiotherapy treatments in pediatric
tumors in our institution.
Method. Between February 2008 and December 2012, thirty one pediatrics patients were treated. Twelve patients had brain tumors
(39%). Seven tumors were planned using a PET-CT 18 FDG (lymphoma, osteosarcoma, nephroblastoma, rhabdomyosarcoma and
neuroblastoma). Immobilizer systems (vacuum mattress and thermoplastic mask) were used in all simulations. Image fusion
with MRI was used in 18 patients and dosimetry with IMRT in 11 tumors (including intrathoracic, retroperitoneal, intracranial
and vertebral tumors). Nine children were treated using FSRT and one patient with SBRT. Doses prescribed were 25.2–54Gy.
Hypofractionated treatments were employed in two reeirradiation cases (30Gy/6Gy/5 fraction). SBRT was used in a mandibular
condyle lesion (24Gy/8Gy/3 fraction) and vertebral metastases (16Gy/8Gy/2 fraction). Treatment veriﬁcation was performed in
all patients: IGRT (conebeam CT) in 12 patients, Novalis ExacTrac in 14 patients and in 5 patients both systems were employed
(craneospinal treatment and intracranial boost in three patients). Most of the patients (90%) received concomitant chemotherapy.
Results. After a median follow up of 14 months (1–60) the local control was achieved in 23 patients. Two patients died due to
progressive distant metastases. Maximal acute toxicities were grade 3 in 9.6% of patients. No acute or chronic toxicity grade 4 or
5 was observed.
Conclusion. The incorporation of MRI, PET-CT 18 FDG, IMRT, FSRT, SBRT and IGRT is a feasible, safety and accurate treatment for
pediatrics tumors. Beneﬁts and toxicities of this approach should be evaluated in prospective clinical trials in order to deﬁne the
role of this advances in pediatric tumors.
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